# U S Physical Therapy Inc: Form 10-Q for the period ended Mar 31, 2012

- Company: [U S Physical Therapy Inc](/companies/usph.md) (CIK 885978)
- Form: 10-Q
- Filed: 2012-05-04
- Accepted by EDGAR: May 4, 2012, 16:07 ET
- Period: 2012-03-31
- Accession: 0001193125-12-210977
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/885978/000119312512210977/d341868d10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/885978/000119312512210977/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2012-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2012-01-01 to 2012-03-31 | $62.6m | us-gaap:SalesRevenueNet |
| Operating income | 3 months, 2012-01-01 to 2012-03-31 | $9.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2012-01-01 to 2012-03-31 | $162.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2012-01-01 to 2012-03-31 | $2.9m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2012-01-01 to 2012-03-31 | $4.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2012-01-01 to 2012-03-31 | $0.38 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2012-01-01 to 2012-03-31 | $0.38 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2012-01-01 to 2012-03-31 | 11,838,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2012-01-01 to 2012-03-31 | $5.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2012-01-01 to 2012-03-31 | $896.0k | us-gaap:PaymentsToAcquireProductiveAssets |
| Dividends paid | 3 months, 2012-01-01 to 2012-03-31 | $1.1m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | at 2012-03-31 | $10.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2012-03-31 | $47.1m | us-gaap:AssetsCurrent |
| Total assets | at 2012-03-31 | $164.4m | us-gaap:Assets |
| Current liabilities | at 2012-03-31 | $12.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2012-03-31 | $38.6m | us-gaap:Liabilities |
| Current portion of debt | at 2012-03-31 | $483.0k | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2012-03-31 | $110.9m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 18,283 characters.

### EXECUTIVE SUMMARY

### Our Business

We operate outpatient physical and/or occupational therapy clinics that provide preventive and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers.

On January 3, 2012, we acquired a 100% interest in a clinic and, effective March 31, 2012, the Company acquired a 65% interest in another clinic. On July 25, 2011, we acquired a 51% interest in a 20 clinic multi-partner physical therapy group (“July 2011 Acquisition”). During the three months ended March 31, 2012, the Company opened two new clinics and closed six clinics.

The results of operations of the acquired clinics have been included in our consolidated financials since the date of their acquisition.

In addition to our owned clinics, we also manage physical therapy facilities for third parties, primarily physicians, with 15 third-party facilities under management as of March 31, 2012.

### Selected Operating and Financial Data

The following table presents selected operating and financial data that we believe are key indicators of our operating performance.

|  | For the Three Months Ended March 31, 2012 | 2011 |
| --- | ---: | ---: |
| Number of clinics, at the end of period | 414 | 397 |
| Working days | 64 | 64 |
| Average visits per day per clinic | 21.8 | 20.4 |
| Total patient visits | 578,670 | 515,161 |
| Net patient revenue per visit | $104.55 | $104.57 |

15

### RESULTS OF OPERATIONS

### Three Months Ended March 31, 2012 Compared to the Three Months Ended March 31, 2011

- Net revenues increased to $62.6 million for the three months ended March 31, 2012 (“2012 First Quarter”) from $56.7 million for the three months ended March 31, 2011 (“2011 First Quarter”) primarily due to an increase in patient visits from 515,000 to 579,000. The average net patient revenue per visit for the 2012 First Quarter was $104.55 as compared to $104.57 in the 2011 First Quarter.
- Net income attributable to our common shareholders for the 2012 First Quarter was $4.5 million versus $3.7 million for the 2011 First Quarter. Net income was $0.38 per diluted share for the 2012 First Quarter as compared to $0.31 per diluted share for the 2011 First Quarter. Total diluted shares were 11.8 million for the 2012 First Quarter and 11.9 million for the 2011 First Quarter.

### Net Patient Revenues

- Net patient revenues increased to $60.5 million for the 2012 First Quarter from $53.9 million for the 2011 First Quarter, an increase of $6.6 million, or 12.3%, primarily due to an increase in patient visits from 515,000 to 579,000.
- The growth in patient visits was primarily attributable to 44,000 visits in clinics opened or acquired between April 1, 2011 and March 31, 2012 (“New Clinics”). For clinics opened or acquired prior to April 1, 2011 (“Mature Clinics”), patient visits increased 20,000 in the 2012 First Quarter as compared to the 2011 First Quarter.
- Net patient revenues related to New Clinics amounted to $4.6 million for the 2012 First Quarter and net patient revenues for Mature Clinics increased $2.0 million for the 2012 First Quarter as compared to the 2011 First Quarter.

Net patient revenues are based on established billing rates less allowances and discounts for patients covered by contractual programs and workers’ compensation. Net patient revenues are after contractual and other adjustments relating to patient discounts from certain payors. Payments received under these programs are based on predetermined rates and are generally less than the established billing rates of the clinics.

### Other Revenues

Other revenues decreased by $0.8 million from $2.9 million to $2.1 million due to lower revenues from physician services, which include clinical services related to intra articular joint and lumbar osteoarthritis programs as well as electro-diagnostic analysis.

### Clinic Operating Costs

Clinic operating costs as a percentage of net revenues were 74.2% for the 2012 First Quarter and 73.3% for the 2011 First Quarter.

### Clinic Operating Costs—Salaries and Related Costs

Salaries and related costs increased to $32.8 million for the 2012 First Quarter from $29.6 million for the 2011 First Quarter, an increase of $3.2 million, or 10.7%. Salaries and related costs for New Clinics amounted to $2.8 million for the 2012 First Quarter. Salaries and related costs for Mature Clinics increased by $0.4 million for the 2012 First Quarter as compared to the 2011 First Quarter. Salaries and related costs as a percentage of net revenues were 52.4% for the 2012 First Quarter and 52.2% for the 2011 First Quarter.

### Clinic Operating Costs—Rent, Clinic Supplies, Contract Labor and Other

Rent, clinic supplies, contract labor and other were $12.5 million for the 2012 First Quarter and $11.3 million for the 2011 First Quarter. For New Clinics, rent, clinic supplies, contract labor and other amounted to $1.3 million for the 2012 First Quarter. For Mature Clinics, rent, clinic supplies, contract labor and other decreased slightly ($0.1 million) in the 2012 First Quarter compared to the 2011 First Quarter. Rent, clinic supplies, contract labor and other as a percentage of net revenues was 19.9% for the 2012 First Quarter and for the 2011 First Quarter.

### Clinic Operating Costs—Provision for Doubtful Accounts

The provision for doubtful accounts was $1.1 million for the 2012 First Quarter and $0.7 million for the 2011 First Quarter. The provision for doubtful accounts for patients accounts receivable as a percentage of net patient revenues was 1.8% for the 2012 First Quarter and 1.2% for the 2011 First Quarter.

Our allowance for doubtful accounts for patient accounts receivable as a percentage of total patient accounts receivable was 6.0% at March 31, 2012, as compared to 7.1% at December 31, 2011. Our days sales outstanding was 48 days at March 31, 2012 and December 31, 2011.

### Corporate Office Costs

Corporate office costs, consisting primarily of salaries and benefits of corporate office personnel, rent, insurance costs, depreciation and amortization, travel, legal, professional, and recruiting fees, were $6.3 million for the 2012 First Quarter and $6.5 million for the 2011 First Quarter. As a percentage of net revenues, corporate office costs were 10.0% for the 2012 First Quarter and 11.4% for the 2011 First Quarter.

### Interest Expense

Interest expense increased to $162,000 in the 2012 First Quarter compared to $73,000 in the 2011 First Quarter due to an increase in the average borrowings outstanding under our revolving credit facility during the 2012 period compared to the 2011 period. At March 31, 2012, $24.2 million was outstanding under our revolving credit facility.

### Provision for Income Taxes

The provision for income taxes increased to $2.9 million for the 2012 First Quarter from $2.4 million for the 2011 First Quarter. During the 2012 and 2011 First Quarters, the Company accrued state and federal income taxes at an effective tax rate (provision for taxes divided by the difference between income before taxes and net income attributable to non-controlling interests) of 39.3%.

### Non-controlling Interests

Net income attributable to non-controlling interests was $2.3 million for the 2012 First Quarter and $2.4 million for the 2011 First Quarter. The reduction is attributable to the Company’s increased ownership interest in certain physical therapy partnerships. Net income attributable to non-controlling interests as a percentage of operating income before corporate office costs was 14.5% for the 2012 First Quarter and 16.1% for the 2011 First Quarter.

### LIQUIDITY AND CAPITAL RESOURCES

We believe that our business is generating sufficient cash flow from operating activities to allow us to meet our short-term and long-term cash requirements, other than those with respect to future acquisitions. At March 31, 2012, we had $10.4 million in cash compared to cash of $10.0 million at December 31, 2011. We believe that our cash and unused availability under our $75.0 million revolving credit facility are sufficient to fund the working capital needs of our operating subsidiaries, corporate costs, dividends, purchases of our common stock, accrued clinic closure costs, future clinic development and investments through at least March 2013. Significant acquisitions of clinics and/or non-controlling interests would likely require financing under our existing revolving credit agreement (defined below).

During the 2012 First Quarter, $5.2 million was provided by operations, $0.7 million was derived from net proceeds from our revolving credit facility and $0.1 million was obtained from the exercise of stock options and related tax benefits and contributions of capital from a limited partner. The major uses of cash included: distributions to non-controlling interest partners ($1.9 million), purchase of businesses ($1.1 million), payments of cash dividends to our shareholders ($1.1 million), purchases of fixed assets ($0.9 million) and payments for acquisitions of non-controlling interests ($0.6 million).

Effective August 27, 2007, we entered into a credit agreement with a commitment for a $30.0 million revolving credit facility which was increased to $50.0 million effective June 4, 2008 (“Credit Agreement”). Effective March 18, 2009, we amended the Credit Agreement to permit us to purchase up to $15,000,000 of our common stock subject to compliance with certain covenants, including the requirement that after giving effect to any stock purchase, our consolidated leverage ratio (as defined in the Credit Agreement) be less than 1.0 to 1.0 and that any stock repurchased be retired within seven days of purchase. Effective October 13, 2010, we amended the Credit Agreement to extend the maturity date from August 31, 2011 to August 31, 2015. In addition, the Credit Agreement was amended to adjust the pricing grid which is based on our consolidated leverage ratio with the applicable spread over LIBOR ranging from 1.6% to 2.5% or the applicable spread over the Base Rate ranging from .1% to 1%. On July 14, 2011, we amended the Credit Agreement to increase the commitment from $50.0 million to $75.0 million. The Credit Agreement is unsecured and has loan covenants, including requirements that we comply with a consolidated fixed charge coverage ratio and consolidated leverage ratio. Proceeds from the Credit Agreement may be used for working capital, acquisitions, purchases of our common stock, dividend payments to our common stockholders, capital expenditures and other corporate purposes. Fees under the Credit Agreement include an unused commitment fee ranging from .1% to .25% depending on our consolidated leverage ratio and the amount of funds outstanding under the Credit Agreement. On March 31, 2012, $24.2 million was outstanding on the revolving credit facility resulting in $50.8 million of availability, and we were in compliance with all of the covenants thereunder.

Historically, we have generated sufficient cash from operations to fund our development activities and to cover operational needs. We plan to continue developing new clinics and making additional acquisitions. We also from time to time purchase the non-controlling interests in our Clinic Partnerships. Generally, any acquisition or purchase of non-controlling interests is expected to be accomplished using a combination of cash and financing. Any large acquisition would likely require financing.

We make reasonable and appropriate efforts to collect accounts receivable, including applicable deductible and co-payment amounts, in a consistent manner for all payor types. Claims are submitted to payors daily, weekly or monthly in accordance with our policy or payor’s requirements. When possible, we submit our claims electronically. The collection process is time consuming and typically involves the submission of claims to multiple payors whose payment of claims may be dependent upon the payment of another payor. Claims under litigation and vehicular incidents can take a year or longer to collect. Medicare and other payor claims relating to new clinics awaiting Medicare Rehab Agency status approval initially may not be submitted for six months or more. When all reasonable internal collection efforts have been exhausted, accounts are written off prior to sending them to outside collection firms. With managed care, commercial health plans and self-pay payor type receivables, the write-off generally occurs after the account receivable has been outstanding for at least 120 days.

We generally enter into various notes payable as a means of financing our acquisitions. Our presently outstanding notes payable relate to acquisitions that occurred in 2012, 2011 and 2010. At March 31, 2012, the balance on these notes payable was $817,000.

In conjunction with acquisitions that occurred in 2010 and 2011, in the event that a limited minority partner’s employment ceases at any time after three years from the acquisition date, we have agreed to repurchase that individual’s non-controlling interest at a predetermined multiple of earnings before interest and taxes.

From September 2001 through December 31, 2008, the Board authorized us to purchase, in the open market or in privately negotiated transactions, up to 2,250,000 shares of our common stock. In March 2009, the Board authorized the repurchase of up to 10% or approximately 1,200,000 shares of our common stock (“March 2009 Authorization”). In connection with the March 2009 Authorization, we amended our bank credit agreement to permit the share repurchases of up to $15,000,000. We are required to retire shares purchased under the March 2009 Authorization. Since there is no expiration date for these share repurchase programs, additional shares may be purchased from time to time in the open market or private transactions depending on price, availability and our cash position. We did not purchase any shares of our common stock during the three months ended March 31, 2012. Using the March 30, 2012 closing price of our common stock (last business day of the three months ended March 31, 2012) of $23.05 per share, there were approximately 147,000 shares remaining that could be purchased under these programs.

### FACTORS AFFECTING FUTURE RESULTS

The risks related to our business and operations include:

- The uncertain economic conditions and the historically high unemployment rate in the United States may have material adverse impacts on our business and financial condition that we currently cannot predict.
- We depend upon reimbursement by third-party payors including Medicare and Medicaid.
- Changes as a result of healthcare reform legislation may affect our business.
- We depend upon the cultivation and maintenance of relationships with the physicians in our markets.
- We also depend upon our ability to recruit and retain experienced physical and occupational therapists.
- Our revenues may fluctuate due to weather.
- Our operations are subject to extensive regulation.
- We operate in a highly competitive industry.
- We may incur closure costs and losses.
- Future acquisitions may use significant resources, may be unsuccessful and could expose us to unforeseen liabilities.
- Certain of our internal controls, particularly as they relate to billings and cash collections, are largely decentralized at our clinic locations.

See Risk Factors in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2011.

### FORWARD LOOKING STATEMENTS

### Forward-Looking Statements

We make statements in this report that are considered to be forward-looking within the meaning under Section 21E of the Securities Exchange Act of 1934. These statements contain forward-looking information relating to the financial condition, results of operations, plans, objectives, future performance and business of our Company. These statements (often using words such as “believes”, “expects”, “intends”, “plans”, “appear”, “should” and similar words) involve risks and uncertainties that could cause actual results to differ materially from those we project. Included among such statements are those relating to opening new clinics, availability of personnel and the reimbursement environment. The forward-looking statements are based on our current views and assumptions and actual results could differ materially from those anticipated in such forward-looking statements as a result of certain risks, uncertainties, and factors, which include, but are not limited to:

- changes in Medicare guidelines and reimbursement or failure of our clinics to maintain their Medicare certification status,
- revenue and earnings expectations;
- general economic conditions;
- business and regulatory conditions including federal and state regulations;
- changes as the result of government enacted national healthcare reform;
- availability and cost of qualified physical and occupational therapists;
- personnel productivity;
- competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain clinics and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets;
- changes in reimbursement rates or payment methods from third party payors including government agencies and deductibles and co-pays owed by patients;
- maintaining adequate internal controls;
- availability, terms, and use of capital;
- acquisitions, purchase of non-controlling interests (minority interests) and the successful integration of the operations of the acquired businesses; and
- weather and other seasonal factors.

Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. Please see our periodic reports filed with the Securities and Exchange Commission (the “SEC”) for more information on these factors. Our forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as required by law, we are under no obligation to update any forward-looking statement, regardless of the reason the statement is no longer accurate.

## Market risk

As filed, 596 characters.

We do not maintain any derivative instruments, interest rate swap arrangements, hedging contracts, futures contracts or the like. The Company’s primary market risk exposure is the changes in interest rates obtainable on our revolving credit agreement. The interest on our revolving credit agreement is based on a variable rate. At March 31, 2012, $24.2 million was outstanding on our revolving credit facility. Based on the balance of the revolving credit facility at March 31, 2012, any change in the interest rate of 1% would yield a decrease or increase in annual interest expense of $242,000.

## Controls and procedures

As filed, 1,373 characters.

(a) Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, the Company’s management completed an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures. Based on this evaluation, our principal executive officer and principal financial officer concluded (i) that our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure and (ii) that our disclosure controls and procedures are effective.

(b) Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Filed May 4, 2012.
Source: SEC EDGAR, the filing index for accession 0001193125-12-210977. Last ingested by Listed: Nov 14, 2026, 13:45 ET. No prices; not investment advice.
